Chondrosarcoma


Chondrosarcoma is a cancer composed of cells derived from transformed cells that produce cartilage. Chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas. About 30% of skeletal system cancers are chondrosarcomas. It is resistant to chemotherapy and radiotherapy. Unlike other primary bone cancers that mainly affect children and adolescents, chondrosarcoma can present at any age. It more often affects the axial skeleton than the appendicular skeleton.

Types

Tissue of OriginType of CancerUsual Location in the BodyMost common ages
Muscle
Striated

muscle
Rhabdomyosarcoma
Embryonal
Head and neck, genitourinary tractInfant–4
Alveolar soft part sarcoma
Arms, legs, head, and neckInfant–19
Smooth

muscle
LeiomyosarcomaTrunk15–19
Fibrous tissueFibrosarcomaArms and legs15–19
Malignant fibrous
histiocytoma
Legs15–19
DermatofibrosarcomaTrunk15–19
FatLiposarcomaArms and Legs15–19
Blood vesselsInfantile hemangio-
pericytoma
Arms, legs, trunk, head, and neckInfant–4
Synovial tissue
Synovial sarcomaLegs, arms, and trunk15–19
Peripheral nervesMalignant peripheral nerve sheath tumors Arms, legs, and trunk15–19
Muscular nervesAlveolar soft part sarcomaArms and legsInfant–19
Cartilage and bone-forming tissueExtraskeletal myxoid chondrosarcomaLegs10–14
Extraskeletal mesenchymalLegs10–14

An earlier version of this article was taken from the US National Cancer Center's Cancer Information Service.

Symptoms

The cause is unknown. Patients may have a history of enchondroma or osteochondroma. A small minority of secondary chondrosarcomas occur in patients with Maffucci syndrome and Ollier disease.
It has been associated with faulty isocitrate dehydrogenase 1 and 2 enzymes, which are also associated with gliomas and leukemias.

Diagnosis

Imaging studies - including radiographs, computerized tomography, and magnetic resonance imaging - are often used to make a presumptive diagnosis of chondrosarcoma. However, a definitive diagnosis depends on the identification of malignant cancer cells producing cartilage in a biopsy specimen that has been examined by a pathologist. In a few cases, usually of highly anaplastic tumors, immunohistochemistry is required.
There are no blood tests currently available to enable an oncologist to render a diagnosis of chondrosarcoma. The most characteristic imaging findings are usually obtained with CT.
Nearly all chondrosarcoma patients appear to be in good health. Often, patients are not aware of the growing tumor until there is a noticeable lump or pain. Earlier diagnosis is generally accidental, when a patient undergoes testing for another problem and physicians discover the cancer. Occasionally the first symptom will be a broken bone at the cancerous site. Any broken bone that occurs from mild trauma warrants further investigation, although there are many conditions that can lead to weak bones, and this form of cancer is not a common cause of such breaks.

Treatment

Treatment depends on the location of the disease and the aggressiveness of the tumors. Because chondrosarcomas are rare, they are treated at specialist hospitals with Sarcoma Centers.
Surgery is the main form of treatment for chondrosarcoma. Musculoskeletal tumor specialists or orthopedic oncologists are usually chosen to treat chondrosarcoma, unless it is located in the skull, spine, or chest cavity, in which case, a neurosurgeon or thoracic surgeon experienced with sarcomas is chosen. Often, a limb-sparing operation can be performed, but in some cases amputation is unavoidable. Amputation of the arm, leg, jaw, or half of the pelvis may be necessary in some cases.
There are two kinds of hemipelvectomy - internal and external.
Amputation at the hip is called hip disarticulation and amputees who have had this amputation are also called hip disartics.
Chemotherapy or traditional radiotherapy are not very effective for most chondrosarcomas, although proton therapy is showing promise with local tumor control at over 80%.
Complete surgical ablation is the most effective treatment, but sometimes this is difficult. Proton therapy radiation can be useful in awkward locations to make surgery more effective.
Recent studies have shown that induction of apoptosis in high-grade chondrosarcoma, both directly and by enhancement of response to chemotherapy and radiation, is a valid therapeutic strategy.

Prognosis

Prognosis depends on how early the cancer is discovered and treated. For the least aggressive grade, about 90% of patients survive more than five years after diagnosis. People usually have a good survival rate at the low grade volume of cancer. For the most aggressive grade, only 10% of patients will survive one year.
Tumors may recur in the future. Follow up scans are extremely important for chondrosarcoma to make sure there has been no recurrence or metastasis, which usually occurs in the lungs.